-

Nexus Pharmaceuticals Announces Diversity Certification

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE). The diversity-based certifications, appointed by the National Minority Supplier Development Council (NMSDC) and the Women’s Business Enterprise National Council (WBENC), have secured Nexus’ status as an MBE and WBE diverse supplier through 2021.

“Nexus Pharmaceuticals is very proud to be a Woman-owned, Minority-owned enterprise,” says Mariam S. Darsot, President and Chief Executive Officer of Nexus Pharmaceuticals. “Moreover, we feel strongly about supporting other diverse enterprises, especially in healthcare. Traditionally, the pharmaceutical industry has lagged behind other industries in diverse supplier adoption and recognition. As one of the few diverse pharmaceutical manufacturers, we are honored to help our healthcare partners meet their diversity goals and open the door for more diverse suppliers.”

To become an NMSDC Certified Minority Business Enterprise (MBE), a minority business must be at least 51% minority-owned, operated, and controlled. Nexus Pharmaceuticals has been a woman-led, minority-owned company since its inception in 2003.

Contacts

Diana Lebiecki
847-996-3790
dlebiecki@nexuspharma.net

Nexus Pharmaceuticals


Release Summary
Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise and a Women’s Business Enterprise.
Release Versions

Contacts

Diana Lebiecki
847-996-3790
dlebiecki@nexuspharma.net

Social Media Profiles
More News From Nexus Pharmaceuticals

Nexus Pharmaceuticals Launches Tacrolimus Injection

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus vial-format solution for healthcare providers and transplant centers to secure essential and cost-effective treatment options. Tacrolimus Injection, USP is a crucial immunosuppressant indicated for the prophylaxis of organ rejection in patients receiving liver or kidney transplants. “We are pleased to share the launch of N...

Nexus Wins Patent Litigation for Injectable Cyclophosphamide, Paving Way for Generic

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Wins Patent Litigation For Injectable Cyclophosphamide, Paving Way For Generic...

Nexus Pharmaceuticals Launches Methylene Blue Injection

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC proudly announces the launch of Methylene Blue Injection, USP. Methylene Blue Injection is indicated for the treatment of methemoglobinemia – a condition that affects the blood’s ability to carry oxygen. “The launch represents a vital addition to Nexus’ growing portfolio of life-saving and difficult-to-manufacture medications,” said Usman Ahmed, CEO of Nexus Pharmaceuticals. “Methylene Blue is a critical drug in emergency care, and...
Back to Newsroom